Shoda, Tetsuo
Kaufman, Kenneth M.
Wen, Ting
Caldwell, Julie M. http://orcid.org/0000-0002-3855-299X
Osswald, Garrett A.
Purnima, Pathre
Zimmermann, Nives http://orcid.org/0000-0002-3624-5435
Collins, Margaret H. http://orcid.org/0000-0002-0756-5974
Rehn, Kira
Foote, Heather
Eby, Michael D.
Zhang, Wenying
Ben-Baruch Morgenstern, Netali http://orcid.org/0000-0001-6530-0387
Ballaban, Adina Y.
Habel, Jeff E.
Kottyan, Leah C. http://orcid.org/0000-0003-3979-2220
Abonia, J. Pablo
Mukkada, Vincent A.
Putnam, Philip E.
Martin, Lisa J. http://orcid.org/0000-0001-8702-9946
Rothenberg, Marc E. http://orcid.org/0000-0001-9790-6332
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R37 AI045898)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01 AI124355, U19 AI070235)
the Campaign Urging Research for Eosinophilic Disease (CURED); the Sunshine Charitable Foundation and its supporters, Denise A. Bunning and David G. Bunning
Article History
Received: 29 September 2020
Accepted: 25 October 2021
First Online: 23 November 2021
Competing interests
: The authors declare competing financial interests. M.E.R. is a consultant for Pulm One, Spoon Guru, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis and has an equity interest in Pulm One, ClostaBio, and Spoon Guru, and royalties from reslizumab (Teva Pharmaceuticals). M.E.R. is an inventor of patents owned by Cincinnati Children’s Hospital Medical Center. M.H.C. is a consultant for Shire, Regeneron, Receptos/Celgene, GlaxoSmithKline, Esocap, Astra Zeneca, Arena, and Allakos and has received research funding from Shire, Regeneron and Receptos/Celgene. V.A.M. is a consultant for Shire and has received research funding from Shire. T.S. has received research support from JSPS Overseas Research Fellowships and is a co-inventor of patents owned by Cincinnati Children’s Hospital Medical Center. All other authors declare no competing interests.